News & Events





Oncodesign integrates OVER-MyR

Oncodesign integrated the OVER MyR network in January 2013 and is now full member of the project. The company will be responsible for the selection of highly potent and selective kinase inhibitors able to overcome MM drug resistance. "This program fits perfectly in our R&D internal initiative focused on Resistance to Targeted Therapies" said Jan Hoflack, CSO of Oncodesign. More info on ONCODESIGN






 Multiple Myeloma and related malignancies
 Bari (Italy)
 Second Edition
 November 7-9, 2013
 ESH International Conference on Multiple Myeloma
 Chairs: A. Palumbo,M. Mateos, G. Morgan
 Dates: October 4-6, 2013
 Venue: Dublin, Ireland



Overmyr © 2012